709 related articles for article (PubMed ID: 28400446)
21. Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Merkel PA; Niles J; Jimenez R; Spiera RF; Rovin BH; Bomback A; Pagnoux C; Potarca A; Schall TJ; Bekker P;
ACR Open Rheumatol; 2020 Nov; 2(11):662-671. PubMed ID: 33128347
[TBL] [Abstract][Full Text] [Related]
22. Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
Nguyen ID; Sinnathamby ES; Mason J; Urban B; Neuchat EE; Wenger DM; Ahmadzadeh S; Shekoohi S; Kaye AD
Clin Drug Investig; 2023 Aug; 43(8):595-603. PubMed ID: 37596445
[TBL] [Abstract][Full Text] [Related]
23. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
JAMA; 2021 Jun; 325(21):2178-2187. PubMed ID: 34061144
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
Bekker P; Dairaghi D; Seitz L; Leleti M; Wang Y; Ertl L; Baumgart T; Shugarts S; Lohr L; Dang T; Miao S; Zeng Y; Fan P; Zhang P; Johnson D; Powers J; Jaen J; Charo I; Schall TJ
PLoS One; 2016; 11(10):e0164646. PubMed ID: 27768695
[TBL] [Abstract][Full Text] [Related]
26. Avacopan for the treatment of ANCA-associated vasculitis.
Osman M; Cohen Tervaert JW; Pagnoux C
Expert Rev Clin Immunol; 2021 Jul; 17(7):717-726. PubMed ID: 34006155
[No Abstract] [Full Text] [Related]
27. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
[TBL] [Abstract][Full Text] [Related]
28. In ANCA-associated vasculitis, avacopan was superior to prednisone taper for sustained remission.
Khan MM; Molony DA
Ann Intern Med; 2021 Jul; 174(7):JC79. PubMed ID: 34224265
[TBL] [Abstract][Full Text] [Related]
29. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Turkiewicz A; Tchao NK; Webber L; Ding L; Sejismundo LP; Mieras K; Weitzenkamp D; Ikle D; Seyfert-Margolis V; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh KA; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Specks U;
N Engl J Med; 2010 Jul; 363(3):221-32. PubMed ID: 20647199
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
31. [Not Available].
Karras A
Nephrol Ther; 2022 Dec; 18(6S1):6S7-6S10. PubMed ID: 36585123
[TBL] [Abstract][Full Text] [Related]
32. AVACOPAN: A New Adjunctive Therapy for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Garg J; Frishman WH
Cardiol Rev; 2023 Jan-Feb 01; 31(1):3-6. PubMed ID: 36469359
[TBL] [Abstract][Full Text] [Related]
33. Avacopan as an additional therapeutic intervention to promote renal recovery in severe ANCA-associated vasculitis: A case report.
Atrens AD; Hutton H; O'Sullivan E; Moore J; Madhan K
Nephrology (Carlton); 2024 Feb; 29(2):105-107. PubMed ID: 37985226
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study.
Harigai M; Kaname S; Tamura N; Dobashi H; Kubono S; Yoshida T
Mod Rheumatol; 2023 Mar; 33(2):338-345. PubMed ID: 35482532
[TBL] [Abstract][Full Text] [Related]
35. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M; Merkel PA; Peh CA; Szpirt WM; Puéchal X; Fujimoto S; Hawley CM; Khalidi N; Floßmann O; Wald R; Girard LP; Levin A; Gregorini G; Harper L; Clark WF; Pagnoux C; Specks U; Smyth L; Tesar V; Ito-Ihara T; de Zoysa JR; Szczeklik W; Flores-Suárez LF; Carette S; Guillevin L; Pusey CD; Casian AL; Brezina B; Mazzetti A; McAlear CA; Broadhurst E; Reidlinger D; Mehta S; Ives N; Jayne DRW;
N Engl J Med; 2020 Feb; 382(7):622-631. PubMed ID: 32053298
[TBL] [Abstract][Full Text] [Related]
36. A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain.
Macía M; Díaz-Encarnación M; Solans-Laqué R; Mallol EP; Castells AG; Escribano C; de Arellano AR
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):227-235. PubMed ID: 38126738
[TBL] [Abstract][Full Text] [Related]
37. Complement Inhibition in ANCA-Associated Vasculitis.
Tesar V; Hruskova Z
Front Immunol; 2022; 13():888816. PubMed ID: 35880179
[TBL] [Abstract][Full Text] [Related]
38. Antineutrophil cytoplasmic antibody (ANCA) vasculitis: pathophysiology, diagnosis, and the evolving treatment landscape.
Koening CL; von Hennigs I
Am J Manag Care; 2021 Sep; 27(15 Suppl):S267-S276. PubMed ID: 34473462
[TBL] [Abstract][Full Text] [Related]
39. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
40. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
